Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.
No pharmacokinetic data located for Vesugen in PubMed/PMC.
No dosing regimen (mcg/mg) reported in either identified human study abstract.
Two small, unblinded human studies (n=32 geroprotection; n=41 vasculogenic erectile dysfunction), both from the same Russian institute lineage (Adv Gerontol, 2014-2015), no blinding described in abstracts, no independent Western replication found. MW 390.39 Da confirmed for the Lys-Glu-Asp tripeptide (PubChem CID 87571363).
No systematic human safety/toxicology dataset exists. The n=32 study reported prooxidant chemiluminescence activity and reduced CD34+ marker counts for the peptide class overall. Absence of reported harm in these small studies is not evidence of safety at scale.
- Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers · journal
- [EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CNS IN REMISSION] · pubmed
- [The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people] · pubmed
- PubChem Compound Summary CID 87571363, Lys-Glu-Asp (MW 390.39) · other